## The role of health determinants in the influenza vaccination uptake among older adults (65+): a scope review

Aging Clinical and Experimental Research

Regina Roller-Wirnsberger (Corresponding Author, Medical University of Graz, Department of Internal Medicine), Sonja Lindner, Lea Kolosovski, Elisabeth Platzer, Peter Dovjak, Holger Flick, Chariklia Tziraki and Maddalena Illario

## **Supplementary Table 1: Study Characteristics**

| No. | Author<br>(Year)               | Continent/<br>Country   | Study design and method  | Participants<br>and setting   | ≥65 years<br>subgroup %<br>(sample) | Outcome<br>(Effect<br>estimate) |
|-----|--------------------------------|-------------------------|--|---|-------------------------------------|---------------------------------|
| 1   | Byeon<br>(2018)                | Asia/<br>South<br>Korea | secondary analysis of a cross-sectional study data retrieved from Korea community health survey (KCHS) questionnaire         | Survey participants ≥ 50 n= 130.610   | 49%<br>n= 64.134                    | vaccine<br>uptake (OR)          |
| 2   | Cha<br>(2016)                  | Asia/<br>South<br>Korea | cross-sectional<br>study<br>data retrieved from<br>KNHANES Survey  | Adults ≥40 years old who underwent pulmonary function testing <i>n</i> =3.224                   | 31%<br>n=1.013                      | vaccine<br>uptake<br>(OR)       |
| 3   | Chang (2016)                   | Asia/<br>Taiwan         | cross-sectional<br>study<br>data retrieved from<br>National Disability<br>Registration<br>System & Health<br>Service Records | Disabled people<br>aged ≥65 years<br>n= 283.172   | 100%                                | vaccine<br>uptake (OR)          |
| 4   | Kwon<br>(2016)                 | Asia/<br>South<br>Korea | secondary analysis<br>of a cross-sectional<br>study<br>data retrieved from<br>KNHANES IV<br>survey<br>questionnaire          | Older adults<br>aged ≥65 years<br>n=3.567   | 100%                                | vaccine<br>uptake<br>(OR)       |
| 5   | Leung<br>(2017)                | Asia/<br>Hong Kong      | randomized<br>controlled trial   | Patients (≥65 years old) of two general outpatient clinics <i>n</i> =529                        | 100%                                | vaccine<br>uptake<br>(RR)       |
| 6   | Mo<br>(2015)                   | Asia/<br>Hong Kong      | cross-sectional<br>study<br>telephone<br>interview   | Older adults<br>aged ≥65 years<br>n=1.101   | 100%                                | vaccine<br>uptake<br>(OR)       |
| 7   | Oh<br>(2015)                   | Asia/<br>South<br>Korea | cross-sectional<br>study<br>questionnaire  | Adult cancer survivors aged ≥19 years old <i>n</i> =35.127                                      | 23%<br>n=8.172                      | vaccine<br>uptake<br>(OR)       |
| 8   | Wershof-<br>Schwartz<br>(2013) | Asia/<br>Israel         | cross-sectional<br>study<br>data retrieved from<br>the Maccabi<br>Healthcare Services<br>(MHS)                               | patients aged ≥65<br>years which are<br>members of MHS<br>n= 136.944<br>mean age: 74.6<br>years | 100%                                | vaccine<br>uptake<br>(OR)       |

| 9  | V.,                          | A sig/                  | arass soational  | community  | 1009/  | reacina                           |
|----|------------------------------|-------------------------|--|--|--|-----------------------------------|
| 9  | Yu<br>(2014)                 | Asia/<br>China          | cross-sectional<br>study<br>face-to-face<br>interviews   | community-<br>dwelling older<br>adults ≥65 years<br>n= 306   | 100%   | vaccine<br>uptake (OR)            |
| 10 | Dyda (2015)                  | Australia/<br>Australia | secondary analysis<br>of a<br>cross-sectional<br>study<br>questionnaire  | participants of<br>the cohort study<br>"45 and Up<br>Study" aged ≥ 45<br>n= 27.036<br>mean age = 65.6<br>years | 28.8%<br>n= 7.785                                      | vaccine<br>uptake (RR)            |
| 11 | Regan<br>(2017)              | Australia/<br>Australia | randomized<br>controlled trial   | high-risk<br>groups <i>n</i> =12.354   | 29%<br>n=3.613   | vaccine<br>uptake<br>(RR)         |
| 12 | Aguilar<br>(2012)            | Europe/<br>Spain        | cross-sectional<br>study<br>data retrieved from<br>vaccination register  | Non-<br>institutionalized<br>persons ≥ 65<br>n= 104.427  | 100%   | vaccine<br>uptake (OR)            |
| 13 | Barbadoro<br>(2016)          | Europe/<br>Italy        | secondary analysis of a cross-sectional study data retrieved from "Health and healthcare use in Italy" Survey questionnaire face-to-face interview | Obese adults in<br>Italy, ≥18 years<br>old<br>n=10.530<br>(2005)<br>n=11.425<br>(2013)                         | 63 %<br>n=2.086<br>(2005)<br>53 %<br>n=2.221<br>(2013) | vaccine<br>uptake<br>(OR)         |
| 14 | Caille-<br>Brillet<br>(2014) | Europe/<br>France       | secondary analysis<br>of a<br>cross-sectional<br>study<br>data retrieved from<br>the CoPanFlu<br>France cohort<br>questionnaire                    | Participants ≥ 15<br>years old of the<br>CoPanFlu France<br>cohort<br>n= 1.174                                 | 22.9%<br>n= 269  | vaccine<br>uptake (OR)            |
| 15 | Domínguez<br>(2016)          | Europe/<br>Spain        | cross-sectional<br>study<br>hospital medical<br>records and<br>questionnaire   | patients aged ≥65 years hospitalized due to causes unrelated to influenza n=1.038                              | 100%   | vaccine<br>uptake<br>(OR)         |
| 16 | Ganczak<br>(2017)            | Europe/<br>Poland       | cross-sectional<br>study<br>questionnaire  | Hospitalized patient ≥65 years old n=230   | 100%   | vaccine<br>uptake<br>(OR)         |
| 17 | Giese<br>(2016)              | Europe/<br>Ireland      | cross-sectional<br>study<br>telephone<br>interview   | adults at-risk and<br>health care<br>workers $\geq$ 18<br>years old<br>n=1.770                                 | 16%<br>n=285   | vaccine<br>uptake<br>(PR)         |
| 18 | Godoy<br>(2015)              | Europe/<br>Spain        | cross-sectional<br>study<br>regional records<br>and survey   | Physician providing patient care for adults ≥65 years <i>n</i> =2.535  | 100%   | vaccine<br>uptake<br>(Prevalence) |

| -  |                            |                               |   |   |                    |  |
|----|----------------------------|-------------------------------|---|---|--------------------|--|
| 19 | Hellfritzsch<br>(2017)     | Europe/<br>Denmark            | cross-sectional<br>study<br>questionnaire   | Older adults (65–79 years) in a tax-<br>supported<br>healthcare system<br><i>n</i> =4.237   | 100%               | vaccine<br>uptake<br>(PR)  |
| 20 | Martínez-<br>Baz<br>(2012) | Europe/<br>Spain              | cross-sectional<br>study<br>data retrieved from<br>vaccination<br>registry  | non-<br>institutionalized<br>persons aged ≥65<br>years registered<br>and who received<br>seasonal vaccine<br>in 2009/10 season<br>n= 64.245 | 100%               | vaccine<br>uptake (OR)   |
| 21 | Poscia<br>(2016)           | Europe/<br>Italy              | Review  | frail elderly<br>people (aged ≥65<br>years)   | 100%               | n.a.   |
| 22 | Shah<br>(2012)             | Europe/<br>England &<br>Wales | cross-sectional<br>study<br>data retrieved from<br>primary care<br>database   | continually registered patients aged 65- 104 from 312 practices in England & Wales n= 387.568 mean age: 85.5 years                          | 100%               | vaccine<br>uptake (RR)   |
| 23 | Spreckelsen<br>(2018)      | Europe/<br>Germany            | secondary analysis<br>of a cross-sectional<br>study<br>data retrieved from<br>claims data of GAK<br>Gesundheit (health<br>insurance fund) | nursing home<br>residents aged<br>≥65 years<br>n=42.068   | 100%               | vaccine<br>uptake<br>(OR)  |
| 24 | Verger<br>(2015)           | Europe/<br>France             | cohort study<br>data retrieved from<br>NHIF database  | patients aged ≥ 18<br>years treated<br>with OHA for<br>type 2 diabetes<br>n= 110.823  | 55.4%<br>n= 61.396 | vaccine<br>uptake (RR)   |
| 25 | Vukovic<br>(2018)          | Europe/<br>Italy              | cohort study data retrieved from Lazio Health and Social Policy Directorate and National Institute for Statistics                         | elderly subjects<br>aged ≥65 years<br>living in the city<br>of Rome from<br>2009-2013<br>n=554.028-<br>590.603                              | 100%               | vaccine<br>uptake<br>(variance)  |
| 26 | Blank<br>(2012)            | 15<br>European<br>Countries   | cross-sectional<br>study<br>questionnaire   | European National Vaccine Industry Groups (NVIGs) (n=16) → relation to vaccine coverage rate among people ≥ 65                              | 100%               | vaccine<br>uptake<br>(correlation<br>coefficient<br>Spearman's<br>Rho) |
| 27 | Banach<br>(2012)           | North<br>America/<br>USA      | cross-sectional<br>study<br>data retrieved from<br>MSVD electronic<br>medical record  | Patients ≥ 65 receiving routine care from MSVD n= 689 Median age: 86 years  | 100%               | vaccine<br>uptake<br>(OR)  |

| 28 | Black<br>(2017)     | North<br>America/<br>USA    | secondary analysis<br>of a cross-sectional<br>study<br>data retrieved from<br>Minimum Data Set<br>(MDS)                      | U.S. nursing home residents, ≥18 years old <i>n</i> =2.446.647 (2005-06) <i>n</i> =2.640.219 (2014-15)  | 86%<br>n=2.113.398<br>(2005-06)<br>84%<br>n=2.215.275<br>(2014-15) | vaccine<br>uptake<br>(OR) |
|----|---------------------|-----------------------------|--|---|--|---------------------------|
| 29 | Farmanara<br>(2018) | North<br>America/<br>Canada | secondary analysis of a cross-sectional study data retrieved from Influenza Immunization Coverage Survey telephone interview | Canadian adults<br>≥18 years old<br>n=1.950   | 26%<br>n=514   | vaccine<br>uptake<br>(OR) |
| 30 | Hurley<br>(2018)    | North<br>America/<br>USA    | randomized<br>controlled trial<br>data retrieved from<br>CIIS  | Adults (19-64 years old) with and without a high-risk condition and adults aged ≥65 years n=47.268      | 11%<br>n=5.332   | vaccine<br>uptake<br>(OR) |
| 31 | Kaljee<br>(2017)    | North<br>America/<br>USA    | qualitative cross-<br>sectional study<br>focus group<br>discussions  | patients at one of<br>three targeted<br>primary care<br>clinics ≥ 65 years<br>n= 48                     | 100%   | vaccine<br>uptake         |
| 32 | Khan<br>(2018)      | North<br>America/<br>USA    | cross-sectional<br>study<br>data retrieved from<br>BRFSS telephone<br>interview  | Older adults<br>aged ≥65 years<br>n=13.106.163  | 100%   | vaccine<br>uptake<br>(OR) |
| 33 | Lu<br>(2014)        | North<br>America/<br>USA    | secondary analysis<br>of a cross-sectional<br>study<br>data retrieved from<br>BRFSS survey<br>telephone<br>interview         | Non-<br>institutionalized<br>U.S. population<br>aged ≥18 years<br>n= 132.743                            | 44.3%<br>n= 58.814   | vaccine<br>uptake (PR)    |
| 34 | Lu (2018)           | North<br>America/<br>USA    | secondary analysis of a cross-sectional study data retrieved from National Internet Flu Survey telephone interview           | Non-institutionalized U.S. population aged ≥18 years <i>n</i> =4.305                                    | 20%<br>n=1.433   | vaccine<br>uptake<br>(PR) |
| 35 | McIntyre<br>(2014)  | North<br>America/<br>Canada | qualitative cross-<br>sectional study<br>focus group<br>discussions  | older adults (aged 67-91) residing in retirement homes or condominium building n= 37 mean age: 82 years | 100%   | vaccine<br>receipt        |

| 36 | Pereira<br>(2019)   | North<br>America/<br>Canada | cross-sectional<br>study<br>survey  | adults aged ≥65<br>years<br>n= 5.014<br>mean age: 71.3<br>years               | 100%                | vaccine<br>uptake (OR)     |
|----|---------------------|-----------------------------|---|---|---------------------|----------------------------|
| 37 | Takayama<br>(2012)  | North<br>America/<br>USA    | secondary analysis<br>of a cross-sectional<br>study<br>data retrieved from<br>BRFSS telephone<br>interview                      | Non-<br>institutionalized<br>U.S. population<br>aged ≥ 18 years<br>n= 420.968 | 31.9%<br>n= 134.101 | vaccine<br>uptake (PR)     |
| 38 | Wooten<br>(2012)    | North<br>America/<br>USA    | secondary analysis of a cross-sectional study data retrieved from National Adult Immunization Survey (NAIS) telephone interview | adults aged ≥65<br>years<br>n= 3.821  | 100%                | vaccine<br>uptake (OR)     |
| 39 | Yokum<br>(2018)     | North<br>America/<br>USA    | randomized<br>controlled trial  | Medicare FFS<br>beneficiaries<br>≥66 years<br>n= 228.000                      | 100%                | vaccine<br>uptake<br>(HR)  |
| 40 | Francisco<br>(2015) | South<br>America/<br>Brazil | secondary analysis<br>of a cross-sectional<br>study<br>data retrieved from<br>FIBRA survey<br>questionnaire                     | Older adults ≥65<br>years old<br>n=679  | 100%                | vaccine<br>uptake<br>(PR)  |
| 41 | Sato<br>(2015)      | South<br>America/<br>Brazil | cross-sectional<br>study<br>questionnaire   | community-<br>dwelling older<br>adults aged ≥60<br>years<br>n=1.341           | 71%<br>n=954        | vaccine<br>uptake<br>(PR)  |
| 42 | Doherty<br>(2016)   | n.a.                        | Review  | Risk groups   | n.a.                | n.a.                       |
| 43 | Kan<br>(2018)       | n.a.                        | systematic review<br>database search  | Older adults<br>aged ≥60 years  | n.a.                | vaccine<br>uptake          |
| 44 | Thomas (2018)       | n.a.                        | systematic review<br>of RCTs<br>database search   | People in the community of high-income countries aged ≥ 60 years n= 1.055.337 | n.a.                | vaccination<br>uptake (OR) |

**Supplementary Table 1.** Supplementary Table 1 shows study characteristics of 44 studies included into final evaluation of the scope review. As may be seen from the figure data on vaccination uptake were collected in countries on five continents (graphically structured by colour) and within care settings ranging from community to hospital and long-term care. Besides adults, also health and social care workforce were asked about vaccination uptake of influenza vaccination using face to face interviews, questionnaires and surveys, telephone interviews. Analysis from data basis such as the Medicare system were also taken into account. Overall, information was collected from 19.604.711 participants in studies included in the final analysis for this scope review.